214 related articles for article (PubMed ID: 21949869)
61. Wnt/Ca2+/NFAT signaling maintains survival of Ph+ leukemia cells upon inhibition of Bcr-Abl.
Gregory MA; Phang TL; Neviani P; Alvarez-Calderon F; Eide CA; O'Hare T; Zaberezhnyy V; Williams RT; Druker BJ; Perrotti D; Degregori J
Cancer Cell; 2010 Jul; 18(1):74-87. PubMed ID: 20609354
[TBL] [Abstract][Full Text] [Related]
62. The ARF tumor suppressor in acute leukemias: insights from mouse models of Bcr-Abl-induced acute lymphoblastic leukemia.
Williams RT; Sherr CJ
Adv Exp Med Biol; 2007; 604():107-14. PubMed ID: 17695724
[TBL] [Abstract][Full Text] [Related]
63. Tetrandrine citrate eliminates imatinib-resistant chronic myeloid leukemia cells in vitro and in vivo by inhibiting Bcr-Abl/β-catenin axis.
Xu XH; Gan YC; Xu GB; Chen T; Zhou H; Tang JF; Gu Y; Xu F; Xie YY; Zhao XY; Xu RZ
J Zhejiang Univ Sci B; 2012 Nov; 13(11):867-74. PubMed ID: 23125079
[TBL] [Abstract][Full Text] [Related]
64. Induction of autophagy by Imatinib sequesters Bcr-Abl in autophagosomes and down-regulates Bcr-Abl protein.
Elzinga BM; Nyhan MJ; Crowley LC; O'Donovan TR; Cahill MR; McKenna SL
Am J Hematol; 2013 Jun; 88(6):455-62. PubMed ID: 23440701
[TBL] [Abstract][Full Text] [Related]
65. Characterization of BCR-ABL deletion mutants from patients with chronic myeloid leukemia.
Sherbenou DW; Hantschel O; Turaga L; Kaupe I; Willis S; Bumm T; Press RD; Superti-Furga G; Druker BJ; Deininger MW
Leukemia; 2008 Jun; 22(6):1184-90. PubMed ID: 18354488
[TBL] [Abstract][Full Text] [Related]
66. Beneficial effects of combining a type II ATP competitive inhibitor with an allosteric competitive inhibitor of BCR-ABL for the treatment of imatinib-sensitive and imatinib-resistant CML.
Weisberg E; Deng X; Choi HG; Barrett R; Adamia S; Ray A; Moreno D; Kung AL; Gray N; Griffin JD
Leukemia; 2010 Jul; 24(7):1375-8. PubMed ID: 20508612
[No Abstract] [Full Text] [Related]
67. Glucose availability in hypoxia regulates the selection of chronic myeloid leukemia progenitor subsets with different resistance to imatinib-mesylate.
Giuntoli S; Tanturli M; Di Gesualdo F; Barbetti V; Rovida E; Dello Sbarba P
Haematologica; 2011 Feb; 96(2):204-12. PubMed ID: 21071498
[TBL] [Abstract][Full Text] [Related]
68. Kinase-addiction and bi-phasic sensitivity-resistance of Bcr-Abl- and Raf-1-expressing cells to imatinib and geldanamycin.
Demidenko ZN; An WG; Lee JT; Romanova LY; McCubrey JA; Blagosklonny MV
Cancer Biol Ther; 2005 Apr; 4(4):484-90. PubMed ID: 15846067
[TBL] [Abstract][Full Text] [Related]
69. Inhibition of wild-type and mutant Bcr-Abl by pyrido-pyrimidine-type small molecule kinase inhibitors.
von Bubnoff N; Veach DR; Miller WT; Li W; Sänger J; Peschel C; Bornmann WG; Clarkson B; Duyster J
Cancer Res; 2003 Oct; 63(19):6395-404. PubMed ID: 14559829
[TBL] [Abstract][Full Text] [Related]
70. Aerobic glycolysis suppresses p53 activity to provide selective protection from apoptosis upon loss of growth signals or inhibition of BCR-Abl.
Mason EF; Zhao Y; Goraksha-Hicks P; Coloff JL; Gannon H; Jones SN; Rathmell JC
Cancer Res; 2010 Oct; 70(20):8066-76. PubMed ID: 20876800
[TBL] [Abstract][Full Text] [Related]
71. BCR-ABL1-independent PI3Kinase activation causing imatinib-resistance.
Quentmeier H; Eberth S; Romani J; Zaborski M; Drexler HG
J Hematol Oncol; 2011 Feb; 4():6. PubMed ID: 21299849
[TBL] [Abstract][Full Text] [Related]
72. Alantolactone induces apoptosis in chronic myelogenous leukemia sensitive or resistant to imatinib through NF-κB inhibition and Bcr/Abl protein deletion.
Wei W; Huang H; Zhao S; Liu W; Liu CX; Chen L; Li JM; Wu YL; Yan H
Apoptosis; 2013 Sep; 18(9):1060-70. PubMed ID: 23613107
[TBL] [Abstract][Full Text] [Related]
73. Synergism between bosutinib (SKI-606) and the Chk1 inhibitor (PF-00477736) in highly imatinib-resistant BCR/ABL⁺ leukemia cells.
Nguyen T; Hawkins E; Kolluri A; Kmieciak M; Park H; Lin H; Grant S
Leuk Res; 2015 Jan; 39(1):65-71. PubMed ID: 25465126
[TBL] [Abstract][Full Text] [Related]
74. Effects of the tyrosine kinase inhibitor imatinib mesylate on a Bcr-Abl-positive cell line: suppression of autonomous cell growth but no effect on decreased adhesive property and morphological changes.
Nishihara T; Miura Y; Tohyama Y; Mizutani C; Hishita T; Ichiyama S; Uchiyama T; Tohyama K
Int J Hematol; 2003 Oct; 78(3):233-40. PubMed ID: 14604282
[TBL] [Abstract][Full Text] [Related]
75. A novel tubulin polymerization inhibitor, MPT0B206, downregulates Bcr-Abl expression and induces apoptosis in imatinib-sensitive and imatinib-resistant CML cells.
Chen CW; Lee YL; Liou JP; Liu YH; Liu CW; Chen TY; Huang HM
Apoptosis; 2016 Sep; 21(9):1008-18. PubMed ID: 27344662
[TBL] [Abstract][Full Text] [Related]
76. Janus kinase 2: a critical target in chronic myelogenous leukemia.
Samanta AK; Lin H; Sun T; Kantarjian H; Arlinghaus RB
Cancer Res; 2006 Jul; 66(13):6468-72. PubMed ID: 16818614
[TBL] [Abstract][Full Text] [Related]
77. Hemin counteracts the repression of Bcl-2 and NrF2 genes and the cell killing induced by imatinib in human Bcr-Abl(+) CML cells.
Bonovolias ID; Tsiftsoglou AS
Oncol Res; 2009; 17(11-12):535-47. PubMed ID: 19806784
[TBL] [Abstract][Full Text] [Related]
78. Functional phosphoproteomic analysis reveals cold-shock domain protein A to be a Bcr-Abl effector-regulating proliferation and transformation in chronic myeloid leukemia.
Sears D; Luong P; Yuan M; Nteliopoulos G; Man YK; Melo JV; Basu S
Cell Death Dis; 2010 Nov; 1(11):e93. PubMed ID: 21368869
[TBL] [Abstract][Full Text] [Related]
79. Targeting 14-3-3 sensitizes native and mutant BCR-ABL to inhibition with U0126, rapamycin and Bcl-2 inhibitor GX15-070.
Dong S; Kang S; Lonial S; Khoury HJ; Viallet J; Chen J
Leukemia; 2008 Mar; 22(3):572-7. PubMed ID: 18079735
[TBL] [Abstract][Full Text] [Related]
80. The PERK-eIF2α phosphorylation arm is a pro-survival pathway of BCR-ABL signaling and confers resistance to imatinib treatment in chronic myeloid leukemia cells.
Kusio-Kobialka M; Podszywalow-Bartnicka P; Peidis P; Glodkowska-Mrowka E; Wolanin K; Leszak G; Seferynska I; Stoklosa T; Koromilas AE; Piwocka K
Cell Cycle; 2012 Nov; 11(21):4069-78. PubMed ID: 23095523
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
